Antimicrobial stewardship programs in inpatient hospital settings: A systematic review

Infection Control and Hospital Epidemiology

Volumn 35, Issue 10, 2014, Pages 1209-1228

  Wagner, Brittin ^a,b   Filice, Gregory A ^a,b   Drekonja, Dimitri ^a,b   Greer, Nancy ^a   MacDonald, Roderick ^a   Rutks, Indulis ^a   Butler, Mary ^c   Wilt, Timothy J ^a,b  

^a Minneapolis Veterans Affairs Health Care System   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIMICROBIAL STEWARDSHIP PROGRAM; ANTIMICROBIAL THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DECISION SUPPORT SYSTEM; HEALTH PROGRAM; HOSPITAL; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL READMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MEDICAL AUDIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS; TREATMENT OUTCOME; DRUG USE; HOSPITAL PATIENT; INFECTION; PROGRAM EVALUATION; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTI-INFECTIVE AGENTS; DRUG UTILIZATION REVIEW; HOSPITALS; HUMANS; INFECTION; INPATIENTS; PROGRAM EVALUATION; TREATMENT OUTCOME;

EID: 84907225125     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1086/678057     Document Type: Review

References (58)

1. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013;368:299-302.
2. Jacob JT, Gaynes RP. Emerging trends in antibiotic use in US hospitals: quality, quantification and stewardship. Expert Rev Anti Infect Ther 2010;8:893-902.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. Chest 1999;115:462-474.
4. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155.
5. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcomes against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010;54:1742-1748.
6. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 2008;47:735-743.
7. Zahar JR, Rioux C, Girou E, et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother 2006;58;651-656.
8. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac arrest. N Engl J Med 2004: 351:1089-1096.
9. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.
10. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18:638-656.
11. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-177.
12. Ohl CA, Dodds Ashley ES. Antimicrobial stewardship programs in community hospitals: the evidence base and case studies. Clin Infect Dis 2011;53(suppl 1):S23-S28.
13. Pope SD, Dellit TH, Owens RC, Hooton TM. Results of the survey on implementation of Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Infect Control Hosp Epidemiol 2009; 30:97-98.
14. Davey P, Brown E, Charani E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4:CD003543. doi: 10.1002/14651858.
15. Cochrane Effective Practice and Organisation of Care Group. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads /Suggested%20risk%20of%20bias%20criteria%20for%20EPOC %20reviews.pdf. Accessed June 5, 2013.
16. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMS TAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
17. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol 2010;63:513-523.
18. Lesprit P, Landelle C, Brun-Buisson C. Clinical impact of unsolicited post-prescription antibiotic review in surgical and medical wards: a randomized controlled trial. Clin Microbiol Infect 2013;19:E91-E97.
19. Camins BC, King MD, Wells JB, et al. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol 2009;30:931-938.
20. Masia M, Matoses C, Padilla S, et al. Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. Eur J Clin Microbiol Infect Dis 2008; 27:597-605.
21. Weiss CH, Moazed F, McEvoy CA, et al. Prompting physicians to address a daily checklist and process of care and clinical outcomes. Am J Respir Crit Care Med 2011;184:680-686.
22. Manuel O, Burnand B, Bady P, et al. Impact of standardised review of intravenous antibiotic therapy 72 hours after prescription in two internal medicine wards. J Hosp Infect 2010;74:326-331.
23. Elligsen M, Walker SAN, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol 2012;33:354-361.
24. Standiford HC, Chan S, Tripoli M, Weekes E, Forrest GN. Antimicrobial stewardship at a large tertiary care academic medical center: cost analysis before, during, and after a 7-year program. Infect Control Hosp Epidemiol 2012;33:338-345.
25. Teo J, Kwa ALH, Loh J, Chlebicki MP, Lee W. The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital. Eur J Clin Microbiol Infect Dis 2012;31:947-955.
26. Bornard L, Dellamonica J, Hyvernat H, et al. Impact of an assisted reassessment of antibiotic therapies on the quality of prescriptions in an intensive care unit. Med Mal Infect 2011;41: 480-485.
27. Dunn K, O’Reilly A, Silke B, Rogers T, Bergin C. Implementing a pharmacist-led sequential antimicrobial therapy strategy: a controlled before-and-after study. Int J Clin Pharm 2011;33:208-214.
28. Cairns KA, Jenney AWJ, Abbott IJ, et al. Prescribing trends before and after implementation of an antimicrobial stewardship program. Med J Aust 2013;198:262-266.
29. Liebowitz LD, Blunt MC. Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate. J Hosp Infect 2008;69:328-336.
30. Magedanz L, Silliprandi EM, dos Santos RP. Impact of the pharmacist on a multidisciplinary team in an antimicrobial stewardship program: a quasi-experimental study. Int J Clin Pharm 2012;34:290-294.
31. Yeo CL, Chan DSG, Earnest A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematologyoncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2012; 31:583-590.
32. Rattanaumpawan P, Sutha P, Thamlikitkul V. Effectiveness of drug use evaluation and antibiotic authorization on patients’ clinical outcomes, antibiotic consumption, and antibiotic expenditures. Am J Infect Control 2010;38:38-43.
33. Peto Z, Benko R, Matuz M, Csullog E, Molnar A, Hajdu E. Results of a local antibiotic management program on antibiotic use in a tertiary intensive care unit in Hungary. Infection 2008; 36:560-564.
34. Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007;120:893-900.
35. Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of highrisk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012;67:2988-2996.
36. Lewis GJ, Fang X, Gooch M, Cook PP. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital’s intensive care and intermediate care units. Infect Control Hosp Epidemiol 2012;33:368-373.
37. Schnoor M, Meyer T, Suttorp N, et al The CAPNETZ Study Group. Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. Qual Saf Health Care 2010;19:498-502.
38. Schouten JA, Hulscher MEJL, Trap-Liefers J, et al. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial. Clin Infect Dis 2007;44:931-941.
39. Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007;59:990-995.
40. Talpaert MJ, Rao GG, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011;66:2168-2174.
41. Goldwater SH, Milkovich G, Morrison AJ, Lindgren B. Comparison of therapeutic interchange with standard educational tools for influencing fluoroquinolone prescribing. Am J Health Syst Pharm 2001;58:1740-1745.
42. Meyer E, Buttler J, Schneider C, et al. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced. J Antimicrob Chemother 2007;59:1148-1154.
43. Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004;39: 955-963.
44. Mangino JE, Peyrani P, Ford KD, et al. Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in HospitalAcquired Pneumonia (IMPACT-HAP) study. Crit Care 2011;15: R38.
45. McGregor JC, Weeks E, Forrest GN, et al. Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. J Am Med Inform Assoc 2006;13:378-384.
46. Barenfanger J, Short MA, Groesch AA. Improved antimicrobial interventions have benefits. J Clin Microbiol 2001;39(8):2823-2828.
47. Nowak MA, Nelson RE, Breidenbach JL, Thompson PA, Carson PJ. Clinical and economic outcomes of a prospective antimi crobial stewardship program. Am J Health Syst Pharm 2012;69: 1500-1508.
48. Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother 2010;65;1062-1069.
49. Carratalà J, Gardia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia. Arch Intern Med 2012;172:922-928.
50. Oosterheert JJ, Bonten MJM, Schneider MME, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomized trial. BMJ 2006;333(7580):1193. doi:10.1136/bmj.38993.560984.BE
51. Pulcini C, Dellamonica J, Bernardin G, Molinari N, Sotto A. Impact of an intervention designed to improve the documentation of the reassessment of antibiotic therapies in an intensive care unit. Med Mal Infect 2011;546-552.
52. Goldstein EJC, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53: 5122-5126.
53. Jensen J, Hein L, Lundgren B, et al; Procalcitonin and Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048-2058.
54. Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomized controlled trial. BMJ Open 2013;3:e002186.
55. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 2011;53(4):379-387.
56. Schuetz P, Miller B, Christ-Crain M, Stoltz D, Tamm M, Bouadma L. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract diseases. Cochrane Database Syst Rev 2012;9:CD007498. doi: 10.1002/14651858.CD007498.pub2.
57. Filice GA, Drekonja DM, Thurn JR, et al. Use of a computer decision support system and antimicrobial therapy appropriateness. Infect Control Hosp Epidemiol 2013;34(6):558-565.
58. Huttner B, Jones M, Rubin MA, et al. Double trouble: how big is a problem is redundant anaerobic antibiotic coverage in Veterans Affairs medical centers? J Antimicrob Chemother 2012;67: 1537-1539.